Full Year 2025 Guidance
BeiGene's financial guidance is summarized below:
| FY 20251 | ||||
| Total Revenue | $4.9 billion to $5.3 billion | |||
| GAAP Operating Expenses (R&D and SG&A) | $4.1 billion to $4.4 billion | |||
| Additional: | GAAP Gross Margin Percentage in mid-80% range | |||
| Positive Full Year GAAP Operating Income | ||||
| Generation of Positive Cash Flow from Operations | ||||
BeiGene's total revenue guidance for full year 2025 of $4.9 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA's U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid-80% range due to mix and production efficiencies as compared to 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.